MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Merck & Co Inc.

Slēgts

SektorsVeselības aprūpe

86.47 -0.15

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

86.26

Max

88.77

Galvenie mērījumi

By Trading Economics

Ienākumi

583M

3.7B

Pārdošana

-1B

16B

P/E

Sektora vidējais

13.318

63.778

EPS

1.72

Dividenžu ienesīgums

3.61

Peļņas marža

23.963

Darbinieki

73,000

EBITDA

1.3B

6.9B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+29.19% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.61%

2.39%

Nākamie ieņēmumi

2025. g. 24. apr.

Nākamais dividenžu datums

2025. g. 7. apr.

Nākamais Ex dividenžu datums

2025. g. 16. jūn.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-26B

227B

Iepriekšējā atvēršanas cena

86.62

Iepriekšējā slēgšanas cena

86.47

Ziņu noskaņojums

By Acuity

39%

61%

145 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Merck & Co Inc. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. febr. 12:33 UTC

Peļņas

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

2025. g. 4. febr. 11:57 UTC

Peļņas

Merck 4Q Sales Increase Results in Swing to Profit

2025. g. 24. marts 05:00 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

2025. g. 5. marts 19:42 UTC

Top Ziņas

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

2025. g. 5. marts 10:30 UTC

Top Ziņas

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

2025. g. 5. febr. 12:00 UTC

Top Ziņas

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

2025. g. 4. febr. 14:48 UTC

Peļņas

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

2025. g. 4. febr. 11:51 UTC

Peļņas

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

2025. g. 4. febr. 11:50 UTC

Peļņas

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

2025. g. 4. febr. 11:31 UTC

Peļņas

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

2025. g. 4. febr. 11:31 UTC

Peļņas

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

2025. g. 4. febr. 11:31 UTC

Peļņas

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

2025. g. 4. febr. 11:31 UTC

Peļņas

Merck 4Q Januvia/Janumet Sales $487M >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck 4Q Keytruda Sales Up 19% >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck 4Q Keytruda Sales $7.84B >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck 4Q Pharmaceutical Sales Up 7% >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck 4Q Pharmaceutical Sales $14.04B >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck Sees FY Adj EPS $8.88-Adj EPS $9.03 >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck: Anticipate Strong Growth in Back Half of 2025, as Well as in Both 2026 and 2027 >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck Sees FY Rev $64.1B-$65.6B >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck: Believe Temporary Pause Will Facilitate a More Rapid Reduction of Excess Inventory >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck: Expect Strength in Oncology and Contributions From Ongoing and New Launches of Important Products in Both Human and Animal Health Businesses to More Than Offset GARDASIL Headwind >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck 4Q Adj EPS $1.72 >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck: Gardasil Market Dynamics in China Do Not in Any Way Diminish the Confidence Co. Has in the Business >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck 4Q Net $3.74B >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck: Excluding Sales of Gardasil in China in Both 2024 and 2025, Expect Strong 2025 Growth Between 7%-9% (Ex-FX) Driven by Continued Strength in Oncology and Animal Health as Well as Contributions From New Product Launches >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck: Sales Outlook Reflects Reassessment of Market for Gardasil/Gardasil 9 in China and Decision to Temporarily Pause Shipments Until at Least Mid-Year >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck Sees FY25 Sales $64.1B-$65.6B >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck: Decline in 4Q Januvia/Janumet Sales Primarily Due to Lower Pricing in U.S., and Ongoing Generic Competition in Many International Markets and Supply Constraints in China >MRK

2025. g. 4. febr. 11:30 UTC

Peļņas

Merck 4Q Winrevair Sales $200M >MRK

Salīdzinājums

Cenas izmaiņa

Merck & Co Inc. Prognoze

Cenas mērķis

By TipRanks

29.19% augšup

Prognoze 12 mēnešiem

Vidējais 111.88 USD  29.19%

Augstākais 138 USD

Zemākais 95 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Merck & Co Inc.  — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

11

Pirkt

6

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 93.07Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

145 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.